title: Collagen metabolites in the prediction of response to GH therapy in short children.
abstract: To evaluate the role of collagen metabolites in the prediction of the response to GH treatment we measured the serum concentrations of the C-terminal propeptide of type I procollagen (PICP) and the N-terminal propeptide of type III procollagen (PIIINP) with specific RIAs in 35 short children (16 boys) before and after 5 days, 5 weeks and 3 months of GH therapy. The mean age of the children was 10.3 years (range 1.9-16.4 years) and the bone age ranged from 1.2 to 12.5 years (mean 7.6 years). The initial mean relative height (RH) was -3.6 SDS (range -6.6 to -2.4 S.D.). Nineteen children were found to have GH deficiency (GHD; peak GH responses in two pharmacological tests < 10 micrograms/l), while the remaining 16 were considered to have undefined short stature (USS). The children were treated with recombinant human GH (0.1 U/kg given subcutaneously at bedtime 6-7 times/week). The increases in RHI over the first 6 and 12 months of therapy were used as response measures. There was already a significant increase (P < 0.001) in both the serum PICP and PIIINP levels at 5 days, and the concentrations continued to rise up to 3 months, PICP levels rising less than the PIIINP levels. In the whole group the RHI over 6 months correlated most strongly with the absolute PICP concentrations at 3 months (rS = 0.59; P < 0.05), while the absolute PIIINP concentrations at 3 months showed the strongest relation to the one year RHI (rS = 0.69; P < 0.001). In the GHD group the 6 month RHI was most strongly related to the absolute PICP concentration at 3 months (rS = 0.59; P < 0.05). In the USS group the absolute PICP concentrations at 3 months correlated most strongly with the one year RHI (rS = 0.82; P < 0.01). Significant correlations were also observed between the absolute PIIINP levels at 3 months and the 6 month RHI (rS = 0.60; P < 0.05) and 12 month RHI (rS = 0.76; P < 0.01) in this group. These results show that GH therapy results in an unequivocal increase in circulating concentrations of PICP and PIIINP. The serum PICP and PIIINP concentrations may be of value in the prediction of the long-term response to GH therapy.
authors.affiliation: Department of Pediatrics, University of Oulu, Finland.
authors.forename: P
authors.initials: P
authors.lastname: Tapanainen
authors.forename: M
authors.initials: M
authors.lastname: Knip
authors.forename: L
authors.initials: L
authors.lastname: Risteli
authors.forename: L
authors.initials: L
authors.lastname: Kemppainen
authors.forename: M L
authors.initials: ML
authors.lastname: Käär
authors.forename: J
authors.initials: J
authors.lastname: Risteli
mesh_terms: D000293:Adolescent; D001846:Bone Development / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003094:Collagen / Q000378:metabolism*; D006130:Growth Disorders / Q000175:diagnosis / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000172:deficiency / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D010446:Peptide Fragments / Q000097:blood; D011863:Radioimmunoassay
chemical_list: D010446:Peptide Fragments; D019382:Human Growth Hormone; D003094:Collagen